HK1166076A1 - Isoquinolin-1 (2h) - one derivatives as parp-1 inhibitors parp-1 -1(2h)- - Google Patents

Isoquinolin-1 (2h) - one derivatives as parp-1 inhibitors parp-1 -1(2h)-

Info

Publication number
HK1166076A1
HK1166076A1 HK12106797.8A HK12106797A HK1166076A1 HK 1166076 A1 HK1166076 A1 HK 1166076A1 HK 12106797 A HK12106797 A HK 12106797A HK 1166076 A1 HK1166076 A1 HK 1166076A1
Authority
HK
Hong Kong
Prior art keywords
parp
isoquinolin
derivatives
inhibitors
inhibitors parp
Prior art date
Application number
HK12106797.8A
Other languages
English (en)
Chinese (zh)
Inventor
.帕佩奧
.伯特蘭
.切爾維
.福特
.盧皮
.蒙塔尼奧利
.斯科拉羅
.祖考圖
.奧希尼
.波斯特裡
Original Assignee
內爾維阿諾醫學科學有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42372343&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1166076(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 內爾維阿諾醫學科學有限公司 filed Critical 內爾維阿諾醫學科學有限公司
Publication of HK1166076A1 publication Critical patent/HK1166076A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • C07D221/18Ring systems of four or more rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/14Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555Hetero-N

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK12106797.8A 2009-05-21 2012-07-11 Isoquinolin-1 (2h) - one derivatives as parp-1 inhibitors parp-1 -1(2h)- HK1166076A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09160869 2009-05-21
PCT/EP2010/056921 WO2010133647A1 (en) 2009-05-21 2010-05-19 Isoquinolin-1 (2h) -one derivatives as parp-1 inhibitors

Publications (1)

Publication Number Publication Date
HK1166076A1 true HK1166076A1 (en) 2012-10-19

Family

ID=42372343

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12106797.8A HK1166076A1 (en) 2009-05-21 2012-07-11 Isoquinolin-1 (2h) - one derivatives as parp-1 inhibitors parp-1 -1(2h)-

Country Status (16)

Country Link
US (2) US8592416B2 (es)
EP (1) EP2432765B1 (es)
JP (1) JP5731486B2 (es)
CN (1) CN102438986B (es)
AR (1) AR076688A1 (es)
AU (1) AU2010251112B2 (es)
BR (1) BRPI1011046B1 (es)
CA (1) CA2762226C (es)
CL (1) CL2011002925A1 (es)
DK (1) DK2432765T3 (es)
EA (1) EA023112B1 (es)
ES (1) ES2568936T3 (es)
HK (1) HK1166076A1 (es)
MX (1) MX2011012187A (es)
TW (1) TWI499418B (es)
WO (1) WO2010133647A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI499418B (zh) 2009-05-21 2015-09-11 Nerviano Medical Sciences Srl 異喹啉-1(2h)-酮衍生物
FR2956816B1 (fr) * 2010-03-01 2012-05-18 Univ Joseph Fourier Utilisation de quinolones pour la preparation de medicaments, nouvelles quinolones et leur procede de synthese
WO2013014038A1 (en) 2011-07-26 2013-01-31 Nerviano Medical Sciences S.R.L. 3-oxo-2,3-dihydro-1h-indazole-4-carboxamide derivatives as parp-1 inhibitors
AU2012342562B2 (en) * 2011-11-25 2017-02-23 Nerviano Medical Sciences S.R.L. 3-phenyl-isoquinolin-1(2H)-one derivatives as PARP-1 inhibitors
CN104302358B (zh) 2012-03-07 2017-12-05 癌症研究协会:皇家癌症医院 3‑芳基‑5‑取代的异喹啉‑1‑酮化合物和它们的治疗用途
SG11201500732TA (en) 2012-08-08 2015-02-27 Merck Patent Gmbh (aza-)isoquinolinone derivatives
KR102200628B1 (ko) 2012-09-26 2021-01-08 메르크 파텐트 게엠베하 Parp 억제제로서의 퀴나졸리논 유도체
US9290454B2 (en) 2012-10-01 2016-03-22 Merck Sharp & Dohme Corp. Substituted isoquinolines as CRTH2 receptor modulators
MX367425B (es) 2012-10-26 2019-08-21 Nerviano Medical Sciences Srl Derivados de 4-carboxamido-isoindolinona como inhibidores selectivos de parp-1.
WO2015036759A1 (en) 2013-09-11 2015-03-19 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
US11261466B2 (en) 2015-03-02 2022-03-01 Sinai Health System Homologous recombination factors
EP3440052B1 (en) 2016-04-06 2023-10-25 University Of Oulu Compounds for use in the treatment of cancer
CN106083716B (zh) * 2016-06-07 2018-10-30 温州医科大学仁济学院 一种3-芳基异喹啉化合物的制备方法
US9891509B2 (en) * 2016-06-17 2018-02-13 Mimono LLC Projector holder
US10899733B2 (en) 2017-08-23 2021-01-26 Oregon Health & Science University Inhibitors of PARPs that catalyze mono-ADP-ribosylation
WO2019232223A1 (en) 2018-05-30 2019-12-05 University Of Notre Dame Du Lac Hsp90 beta selective inhibitors
CN113549044B (zh) * 2021-07-23 2024-01-23 中国药科大学 8-氮杂环取代色酮类衍生物及其制备方法与制药用途
WO2023242302A1 (en) 2022-06-15 2023-12-21 Astrazeneca Ab Combination therapy for treating cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59116269A (ja) * 1982-12-24 1984-07-05 Nisshin Flour Milling Co Ltd イソカルボスチリル誘導体
JPS60237070A (ja) * 1984-05-08 1985-11-25 Nisshin Flour Milling Co Ltd 光学活性イソカルボスチリル誘導体の製法
DK0389995T3 (da) 1989-03-28 1995-07-03 Nisshin Flour Milling Co Isoquinolinderivater til behandling af glaukom eller okular hypertension
JP3141051B2 (ja) 1992-10-09 2001-03-05 日清製粉株式会社 抗動脈硬化剤
SE9902268D0 (sv) * 1999-06-16 1999-06-16 Astra Ab Pharmaceutically active compounds
ATE355278T1 (de) * 2001-05-08 2006-03-15 Kudos Pharm Ltd Isochinolinon derivate als parp inhibitoren
JP4520406B2 (ja) * 2002-10-01 2010-08-04 田辺三菱製薬株式会社 イソキノリン化合物及びその医薬用途
ES2376166T3 (es) * 2002-11-22 2012-03-09 Mitsubishi Tanabe Pharma Corporation Compuestos de isoquinolina y su uso medicinal.
DE102004028973A1 (de) * 2004-06-16 2006-01-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
US8389544B2 (en) 2007-01-17 2013-03-05 The Hong Kong University Of Science And Technology Isoquinolone compounds as subtype-selective agonists for melatonin receptors MT1 and MT2
TWI499418B (zh) 2009-05-21 2015-09-11 Nerviano Medical Sciences Srl 異喹啉-1(2h)-酮衍生物

Also Published As

Publication number Publication date
AU2010251112A1 (en) 2012-01-19
JP2012527428A (ja) 2012-11-08
AU2010251112A2 (en) 2012-02-02
JP5731486B2 (ja) 2015-06-10
EP2432765A1 (en) 2012-03-28
MX2011012187A (es) 2012-01-27
TW201043232A (en) 2010-12-16
US20140045846A1 (en) 2014-02-13
CA2762226C (en) 2017-12-05
CN102438986B (zh) 2015-07-01
AR076688A1 (es) 2011-06-29
AU2010251112B2 (en) 2015-11-12
CL2011002925A1 (es) 2012-04-13
CA2762226A1 (en) 2010-11-25
US8592416B2 (en) 2013-11-26
WO2010133647A1 (en) 2010-11-25
EA201171448A1 (ru) 2012-06-29
EA023112B1 (ru) 2016-04-29
BRPI1011046B1 (pt) 2020-02-27
ES2568936T3 (es) 2016-05-05
CN102438986A (zh) 2012-05-02
US8993594B2 (en) 2015-03-31
TWI499418B (zh) 2015-09-11
EP2432765B1 (en) 2016-03-02
DK2432765T3 (en) 2016-04-25
BRPI1011046A2 (pt) 2016-03-15
US20120157454A1 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
HK1166076A1 (en) Isoquinolin-1 (2h) - one derivatives as parp-1 inhibitors parp-1 -1(2h)-
HK1179477A1 (en) Kinase inhibitors
ZA201203842B (en) Kinase inhibitors
IL202834A0 (en) Phthalazinone derivatives as inhibitors of parp-1
EP2558099A4 (en) Kinase Inhibitors
EP2396004A4 (en) SELECTIVE KINASE HEMMER
EP2515657A4 (en) TYROSINE KINASE INHIBITORS
ZA201305992B (en) 5-fluoro-2-oxopyrimidine-1(2h)-carboxylate derivatives
HK1171915A1 (en) N1-substituted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives n1--5--2--1(2h)-
IL214293A0 (en) Dihydroquinolinone derivatives
HK1164853A1 (en) Pyridazinone derivatives
EP2231152A4 (en) THIENOPYRANONES AS KINASE INHIBITORS
EP2480076A4 (en) IMIDAZOTHIAZOLIC INHIBITORS OF KINASES
EP2496230A4 (en) INHIBITORS OF IRE-1 ALPHA
HK1200166A1 (en) 3-phenyl-isoquinolin-1(2h)-one derivatives as parp-1 inhibitors parp-1 3---1(2h)-
IL219872A0 (en) Quinazoline derivatives
EP2436470A4 (en) REAMER
GB0914726D0 (en) Kinase inhibitors
EP2344472A4 (en) ISOCHINOLINONDERIVATE
ZA201105781B (en) Pyridazinone derivatives
ZA200908789B (en) Phthalazinone derivatives as inhibitors of parp-1